May 11, 2021
Business News

Cicero Diagnostics Hits Record Growth For First Quarter 2021


HUNTINGTON BEACH, Calif.–()–Cicero Diagnostics Inc., a women’s healthcare diagnostic company offering the ReceptivaDx™ test for unexplained infertility, today announced it has reached several record milestones ending the quarter March 31. Sample volume year over year grew 250%. As of March 31, 2021, over 700 Reproductive Endocrinologists in the U.S. now access ReceptivaDx™, representing 80% of all fertility centers in the country. The company also reported that international volume now originates from five continents around the world, with major agreements recently signed in Dubai, Cairo and the Philippines.

The ReceptivaDx™ test detects inflammation on the uterine lining, most often caused by…



Click here to view the original article.

Related Posts

You might also like ...

Reltio CEO, Chris Hylen, Named a Top Executive on CRN Annual Big Data 100 List of Top Data Innovators
CPI Card Group Inc. Reports First Quarter 2021 Results
SuperDraft Announces Plans to Expand Into iGaming With Game Play Network